TLSA Stock Analysis: Buy, Sell, or Hold?
TLSA - Tiziana Life Sciences Ltd. Common Shares
$0.95
-0.06 (-5.94%)
âŧ
5d:
-9.52%
30d:
-9.52%
90d:
+6.44%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Aug 07, 2026
0d
Get Alerted When TLSA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: TLSA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: TLSA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: TLSA is currently trading at $0.95, which is considered fair relative to its 30-day fair value range of $0.92 to $1.12.
Technical Outlook: Technically, TLSA is in a downtrend. The price is currently testing key support at $0.97. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.9% recently.
Market Sentiment: TLSA scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.08 (+700.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TLSA is in a downtrend. The price is currently testing key support at $0.97. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.9% recently.
Market Sentiment: TLSA scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.08 (+700.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.92 -
$1.12
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
44.7%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (20/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.9%)
- BULLISH: Trading 700.4% below Wall St target ($8.08)
- WARNING: Composite score 37/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.92 -
$1.12
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$0.97
Resistance Level
$1.25
Current Trend
Downtrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.43
Wall Street Target
$8.08
(+700.4%)
Share & Embed Analysis
Last updated: October 22, 2026 11:31 AM ET
Data refreshes hourly during market hours. Next update: 12:31 PM
Data refreshes hourly during market hours. Next update: 12:31 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TLSA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
STRONG BUY
25 analysts |
$84 | 69 BUY |
|
RVMD
Revolution Medicines Inc |
STRONG BUY
24 analysts |
$258 | 58 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
21 analysts |
$95 | 59 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$72 | 60 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
